A UW Medicine-based study shows most Merkel cell carcinoma recurrences happen in the first three years after treatment.
Survival rates seen today among patients with advanced Merkel cell carcinoma were unheard-of with chemotherapy.
UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer.
Frisco, Texas, resident Steve Murphy, 66, was diagnosed last September with Merkel cell carcinoma, a rare skin cancer he’d never heard of. His grim prognosis: 50 percent chance of surviving 90 days.
Aging baby boomers are anticipated to propel cases of Merkel cell carcinoma, an often-fatal disease.
Many patients with advanced Merkel cell carcinoma who received the immunotherapeutic pembrolizumab as first-line therapy in a
